NUCLEAR IMAGING EQUIPMENT MARKET ANALYSIS

Nuclear Imaging Equipment Market, By Product Type (Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Hybrid PET-CT, Hybrid SPECT-CT, Hybrid PET-MRI, and Others), By Application (Oncology, Cardiology, Neurology, and Others), By End User (Hospitals and clinics, Diagnostic imaging centers, Research institutes, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Recent Developments:

New product launches:

In June 12, 2022, Siemens Healthineers, a medical device company, introduces Symbia Pro.specta, a single photon emission computed tomography/computed tomography (SPECT/CT) system with CE mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging technologies.
In October 15, 2019, Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis, announced publication of a study evaluating the use of a positron emission tomography (PET) tracer for the detection of idiopathic pulmonary fibrosis (IPF) through the recognition of protein integrin avb6.

Acquisition and Partnerships:

In October 10, 2023, Medicines Discovery Catapult (MDC), the Medical Research Council (MRC) and Innovate U.K. via partnership launched A US$ 35.1 million total-body positron emission tomography (PET) imaging platform for drug discovery